Regeneron Pharmaceuticals has entered a clinical study agreement with Inovio Pharmaceuticals to conduct its Phase Ib/IIa clinical trial of REGN2810 in combination with INO-5401 and INO-9012 to treat patients with newly diagnosed glioblastoma multiforme (GBM).

REGN2810 is a PD-1 inhibitor, while Inovio's INO-9012 is an immune activator that encodes IL-12 and INO-5401 is a T-cell activating immunotherapy that encodes various antigens.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Set to be commenced in the coming months, the open-label Phase Ib/IIa trial will assess the safety and efficacy of the combination in up to 50 subjects at 30 US clinical centres.

Regeneron translation sciences and oncology vice-president Israel Lowy said: "Regeneron's approach to oncology includes evaluating the combination of innovative therapies that act on diverse pathways and targets.

"Regeneron's approach to oncology includes evaluating the combination of innovative therapies that act on diverse pathways and targets."

"Using our PD-1 inhibitor as a therapeutic backbone alongside Inovio's T-cell-generating therapies offers a new path for exploration and heightens the potential to develop new, desperately needed treatment options for patients."

See Also:

The primary endpoints of the trial are safety and tolerability, while the immunological impact, progression-free survival and overall survival will also be examined during the treatment period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Inovio president and chief executive officer Joseph Kim said: "This step with INO-5401 is very important for us in 2017, as we believe INO-5401 has the potential to be a powerful cancer immunotherapeutic in combination with promising checkpoint inhibitors such as Regeneron's REGN2810, and we look forward to investigating its potential for GBM and multiple other challenging cancers."

Under the clinical study agreement, Inovio will conduct and fund the trial with mutually agreed design, while Regeneron will supply REGN2810, which is currently being developed in partnership with Sanofi.

Regeneron and Inovio will jointly perform the immunological analyses related to the trial.